AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea

Keyphrases

• Clinical Practice Guidelines 100%
• Irritable Bowel Syndrome 100%
• Pharmacological Management 100%
• Rifaximin 50%
• Selective Serotonin Reuptake Inhibitors 50%
• Tricyclic Antidepressants 50%
• Loperamide 50%
• Technical Review 50%
• Eluxadoline 50%
• Alosetron 50%
• Medication Use 25%
• Assessment Development 25%
• Evaluation Assessment 25%
• Evaluation Framework 25%
• Patient Management 25%
• Assessment Framework 25%
• Development Framework 25%
• Significant Disease 25%
• Grading of Recommendations 25%
• Technical Guidelines 25%
• Functional Gastrointestinal Disorders 25%
• Antispasmodic 25%
• Guideline Panel 25%
• Review Panel 25%
• American Gastroenterological Association 25%
• Evidence to Decision Framework 25%
• Diarrhea-predominant Irritable Bowel Syndrome 25%
• Evidence Review 25%
• Disease Burden 25%

Medicine and Dentistry

• Diarrhea 100%
• Irritable Bowel Syndrome 100%
• Selective Serotonin Reuptake Inhibitor 40%
• Rifaximin 40%
• Tricyclic Antidepressant 40%
• Alosetron 40%
• Eluxadoline 40%
• Loperamide 40%
• Clinician 20%
• Disease Burden 20%
• Antispasmodic 20%
• Functional Gastrointestinal Disorder 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Diarrhea 100%
• Irritable Colon 100%
• Tricyclic Antidepressant 40%
• Loperamide 40%
• Rifaximin 40%
• Selective Serotonin Reuptake Inhibitor 40%
• Eluxadoline 40%
• Alosetron 40%
• Digestive System Function Disorder 20%
• Spasmolytic Agent 20%
• Diseases 20%